Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets

Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets

Alzheimer's disease (AD) is characterized by an accumulation of β-amyloid (Aβ42) accompanied by brain atrophy and cognitive decline. Several recent studies have shown that Aβ42 accumulation is associated with gray matter (GM) changes prior to the development of cognitive impairment, in the so-c...

Full description

Bibliographic Details
Main Authors:	Carles Falcon, Alan Tucholka, Gemma C. Monté-Rubio, Raffaele Cacciaglia, Grégory Operto, Lorena Rami, Juan Domingo Gispert, José Luis Molinuevo
Format:	Article
Language:	English
Published:	Elsevier 2018-01-01
Series:	NeuroImage: Clinical
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213158218301256

Similar Items

A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease
by: Murat Demirtaş, et al.
Published: (2017-01-01)

Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer’s disease
by: Stavros Skouras, et al.
Published: (2019-01-01)

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals
by: Carles Falcon, et al.
Published: (2019-01-01)

APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals
by: Raffaele Cacciaglia, et al.
Published: (2019-01-01)

Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI
by: Paula M. Petrone, et al.
Published: (2019-08-01)

Management and Quality Control of Large Neuroimaging Datasets: Developments From the Barcelonaβeta Brain Research Center
by: Jordi Huguet, et al.
Published: (2021-04-01)

Interactive effect of age and APOE-ε4 allele load on white matter myelin content in cognitively normal middle-aged subjects
by: Grégory Operto, et al.
Published: (2019-01-01)

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
by: Gemma Salvadó, et al.
Published: (2019-03-01)

White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes
by: Grégory Operto, et al.
Published: (2018-05-01)

Genetic Predisposition to Alzheimer’s Disease Is Associated with Enlargement of Perivascular Spaces in Centrum Semiovale Region
by: Iacopo Ciampa, et al.
Published: (2021-05-01)

Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
by: Ling-Zhi Ma, et al.
Published: (2020-04-01)

Brain correlates of urban environmental exposures in cognitively unimpaired individuals at increased risk for Alzheimer's disease: A study on Barcelona's population
by: Carles Falcón, et al.
Published: (2021-01-01)

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease
by: Victoria Monge-García, et al.
Published: (2021-09-01)

Harmonization of CSF and imaging biomarkers in Alzheimer's disease: Need and practical applications for genetics studies and preclinical classification
by: Jigyasha Timsina, et al.
Published: (2024-01-01)

Autosomal dominant Alzheimer disease: A unique resource to study CSF biomarker changes in preclinical AD
by: Suzanne Elizabeth Schindler, et al.
Published: (2015-06-01)

Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer’s disease
by: Neus Barranco, et al.
Published: (2021-09-01)

Cognitively unimpaired individuals with a low burden of Aβ pathology have a distinct CSF biomarker profile
by: Marta Milà-Alomà, et al.
Published: (2021-07-01)

Spatial patterns of white matter hyperintensities associated with Alzheimer’s disease risk factors in a cognitively healthy middle-aged cohort
by: Gemma Salvadó, et al.
Published: (2019-01-01)

APOE ϵ4 Allele Is Associated with Elevated Levels of CSF VILIP-1 in Preclinical Alzheimer’s Disease
by: Wang L, et al.
Published: (2020-04-01)

Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer’s dementia
by: Marta Crous-Bou, et al.
Published: (2020-05-01)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
by: Ashvini Keshavan, et al.
Published: (2021-01-01)

Chemokines in CSF of Alzheimer's disease patients
by: Jôice Dias Corrêa, et al.
Published: (2011-06-01)

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
by: Juan Lantero‐Rodriguez, et al.
Published: (2021-12-01)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
by: Ruocheng Dong, et al.
Published: (2021-01-01)

Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex
by: Irene Cumplido-Mayoral, et al.
Published: (2023-04-01)

Meta-Review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria
by: Daniel eFerreira, et al.
Published: (2014-03-01)

APOE -ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals
by: Anna Brugulat-Serrat, et al.
Published: (2023-03-01)

Decreased CSF acetylcholinesterase activity in Alzheimer's disease.
by: Appleyard, M, et al.
Published: (1983)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
by: Betty Marije Tijms, et al.
Published: (2021-08-01)

Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: do fresh vs frozen samples differ?
by: Giovanni Bellomo, et al.
Published: (2020-09-01)

Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer’s disease core biomarkers in Lewy body disorders and Alzheimer’s dementia
by: Davide Chiasserini, et al.
Published: (2017-07-01)

Modeling practice effects in healthy middle‐aged participants of the Alzheimer and Families parent cohort
by: Gonzalo Sánchez‐Benavides, et al.
Published: (2016-01-01)

Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
by: Kun Zou, et al.
Published: (2020-08-01)

CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
by: Ruocheng Dong, et al.
Published: (2023-08-01)

CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease
by: Delvenne, A, et al.
Published: (2024)

CSF P-tau 231 as biomarker in alzheimer's disease
by: Adreesh Mukherjee, et al.
Published: (2022-01-01)

Exacerbated CSF abnormalities in younger patients with Alzheimer's disease
by: Julien Dumurgier, et al.
Published: (2013-06-01)

Levels of ADAM10 are reduced in Alzheimer’s disease CSF
by: Aitana Sogorb-Esteve, et al.
Published: (2018-07-01)

CSF p-Tau levels in the prediction of Alzheimer's disease
by: Ramesh J. L. Kandimalla, et al.
Published: (2013-09-01)

Volume transmission of CSF: complications in aging and Alzheimer's disease
by: Duncan J, et al.
Published: (2004-12-01)